Mitochondrial fission – a drug target for cytoprotection or cytodestruction?

Mitochondria are morphologically dynamic organelles constantly undergoing processes of fission and fusion that maintain integrity and bioenergetics of the organelle: these processes are vital for cell survival. Disruption in the balance of mitochondrial fusion and fission is thought to play a role i...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology research & perspectives 2016-06, Vol.4 (3), p.e00235-n/a
Main Authors: Rosdah, Ayeshah A., K. Holien, Jessica, Delbridge, Lea M. D., Dusting, Gregory J., Lim, Shiang Y.
Format: Article
Language:English
Subjects:
Apoptosis
Cardiomyocytes
Cell cycle
Cell death
Cytotoxicity
Deoxyribonucleic acid
DNA
Invited Review
Invited Reviews
Kinases
Mdivi‐1
Medical research
Metabolism
Metabolites
Mitochondria
Mitochondrial DNA
mitochondrial fission
mitochondrial fusion
Pharmacology
Phosphorylation
Physiology
Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mitochondria are morphologically dynamic organelles constantly undergoing processes of fission and fusion that maintain integrity and bioenergetics of the organelle: these processes are vital for cell survival. Disruption in the balance of mitochondrial fusion and fission is thought to play a role in several pathological conditions including ischemic heart disease. Proteins involved in regulating the processes of mitochondrial fusion and fission are therefore potential targets for pharmacological therapies. Mdivi‐1 is a small molecule inhibitor of the mitochondrial fission protein Drp1. Inhibiting mitochondrial fission with Mdivi‐1 has proven cytoprotective benefits in several cell types involved in a wide array of cardiovascular injury models. On the other hand, Mdivi‐1 can also exert antiproliferative and cytotoxic effects, particularly in hyperproliferative cells. In this review, we discuss these divergent effects of Mdivi‐1 on cell survival, as well as the potential and limitations of Mdivi‐1 as a therapeutic agent.
ISSN:2052-1707
2052-1707
DOI:10.1002/prp2.235